BOSTON SCIENTIFIC CORP (BSX:NYSE)
$64.23 0.81 (1.2772%)
Analysed BOSTON SCIENTIFIC CORP (BSX:NYSE) News Sources
How FDA-Cleared Asurys and Galway R&D Expansion At Boston Scientific (BSX) Has Changed Its Investment Story
18-04-2026
yahoo.com
1 Cash-Producing Stock for Long-Term Investors and 2 That Underwhelm
18-04-2026
yahoo.com
Will Robust Cardiovascular Performance Fuel BSX's Q1 Earnings?
17-04-2026
yahoo.com
Boston Scientific Corporation (BSX) Price Target Lowered at Mizuho Ahead of Q1 Medical Device Earnings
17-04-2026
yahoo.com
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
17-04-2026
yahoo.com
Intuitive Surgical Pre-Q1 Analysis: Buy, Hold or Sell the Stock Now?
16-04-2026
yahoo.com
Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026
16-04-2026
yahoo.com
Envoy Medical Appoints Chas McKhann to Board of Directors
16-04-2026
yahoo.com
Boston Scientific plans $88.5M R&D expansion in Ireland
16-04-2026
medtechdive.com
Revisiting Stock Picks Burlington Stores, Boston Scientific, Pinterest
16-04-2026
yahoo.com
What is the current price of BOSTON SCIENTIFIC CORP (BSX:NYSE)?
The current price of BOSTON SCIENTIFIC CORP (BSX:NYSE) is $64.23.
BOSTON SCIENTIFIC CORP (BSX:NYSE) absolute price change since previous trading day?
The absolute price change of BOSTON SCIENTIFIC CORP (BSX:NYSE) since the previous trading day is $0.81.
BOSTON SCIENTIFIC CORP (BSX:NYSE) percentage price change since previous trading day?
The percentage price change of BOSTON SCIENTIFIC CORP (BSX:NYSE) since the previous trading day is 1.2772%.
What is the most recent average sentiment score for BOSTON SCIENTIFIC CORP (BSX:NYSE)?
The most recent average sentiment score for BOSTON SCIENTIFIC CORP (BSX:NYSE) is 74 out of 100.
What is the most recent average sentiment for BOSTON SCIENTIFIC CORP (BSX:NYSE)?
The most recent sentiment for BOSTON SCIENTIFIC CORP (BSX:NYSE) is .
SEC-8K** Filing Available For BOSTON SCIENTIFIC CORP (BSX:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.